Obesity treatment: novel peripheral targets
Open Access
- 27 November 2009
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 68 (6), 830-843
- https://doi.org/10.1111/j.1365-2125.2009.03522.x
Abstract
Our knowledge of the complex mechanisms underlying energy homeostasis has expanded enormously in recent years. Food intake and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status. Several gut hormones, including cholecystokinin, glucagon‐like peptide‐1, peptide YY, oxyntomodulin, amylin, pancreatic polypeptide and ghrelin, have been shown to play an important role in regulating short‐term food intake. These hormones therefore represent potential targets in the development of novel anti‐obesity drugs. This review focuses on the role of gut hormones in short‐ and long‐term regulation of food intake, and on the current state of development of gut hormone‐based obesity therapies.Keywords
This publication has 214 references indexed in Scilit:
- Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin AloneDiabetes Care, 2009
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet, 2009
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)Diabetes Care, 2009
- Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)Diabetic Medicine, 2009
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 DiabetesDiabetes Care, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in ObesityDiabetes Care, 2008
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studiesProceedings of the National Academy of Sciences, 2008
- Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1Proceedings of the National Academy of Sciences, 2007
- Vaccination against weight gainProceedings of the National Academy of Sciences, 2006